Phathom Pharmaceuticals, Inc. (PHAT) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Phathom Pharmaceuticals is a biopharmaceutical company commercializing vonoprazan-based products (VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK) for gastrointestinal diseases in the U.S. The company operates as a single segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Product Revenue, Net | $39.5 million | $68.0 million | $9.2 million |
| Gross Profit | $34.5 million | $59.3 million | $7.4 million |
| Gross Margin | 87.3% | 87.1% | 80.5% |
| Net Loss | $(75.8) million | $(170.1) million | $(174.3) million |
| Operating Cash Flow | N/A | $(147.7) million | $(139.7) million |
| Cash & Equivalents (End of Period) | $149.6 million | $149.6 million | $279.1 million (YTD 2024 end) |
| Total Debt (Net) | $205.1 million | $205.1 million | $201.4 million |
| Revenue Interest Liability | $368.5 million | $368.5 million | $353.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net product revenue increased significantly to $39.5 million in Q2 2025 from $7.3 million in Q2 2024, driven by the commercial launch momentum of VOQUEZNA products.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose to $85.3 million in Q2 2025 from $75.9 million in Q2 2024. This increase includes approximately $8.9 million in restructuring charges related to a workforce reduction of 28 employees (approx. 6%) implemented in May 2025.
- Interest Expense: Total interest expense remained relatively stable at $17.5 million for Q2 2025 compared to $17.8 million in Q2 2024, despite higher debt balances, due to lower interest rates on the Hercules Loan Agreement.
- Liquidity: Cash and cash equivalents decreased by approximately $147.7 million during the first six months of 2025, primarily due to operating cash burn and inventory build-up.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash ($149.6 million) and anticipated product revenues are sufficient to fund operations for at least the next twelve months.
- Debt Covenants: The company is currently in compliance with all covenants under its Hercules Loan Agreement. However, it does not expect to meet the revenue threshold required to draw the Sixth Tranche ($50 million) by December 31, 2025.
- Supply Chain Risk: The company has been informed of a potential disruption in the supply of clarithromycin tablets, a component of VOQUEZNA TRIPLE PAK (approx. 1% of total revenue). While no commercial disruption has occurred to date, a supply failure would halt commercialization of this specific product.
- Restructuring: The May 2025 restructuring plan incurred $8.0 million in charges to reduce cash burn and focus on commercial execution. Approximately $2.6 million in restructuring accruals remain on the balance sheet.
- Regulatory: The FDA updated the Orange Book listing for VOQUEZNA tablets to reflect a full ten-year period of New Chemical Entity (NCE) exclusivity through May 3, 2032.
Investor Verification Checklist
- Revenue Sustainability: Verify the trajectory of VOQUEZNA sales growth against the high SG&A burn rate to assess the path to profitability.
- Debt Obligations: Review the terms of the Revenue Interest Financing Liability ($368.5 million) and the Hercules Loan ($214.1 million principal) to understand future cash outflows and royalty obligations.
- Supply Chain Status: Monitor updates regarding the clarithromycin supply disruption and its potential impact on the VOQUEZNA TRIPLE PAK product line.
- Cash Runway: Confirm the accuracy of the 12-month liquidity projection given the high operating cash burn of $147.7 million in the first half of 2025.
- Restructuring Impact: Assess whether the $8.0 million restructuring charge and workforce reduction will result in sustained SG&A reductions in future quarters.